WO2023080664A1 - Metabolite marker for predicting therapy responsiveness in patients with mycobacterium avium complex - Google Patents

Abstract

The present invention relates to a composition for predicting antibiotic therapy responsiveness in patients infected with nontuberculous mycobacteria by measuring a specific metabolite in blood. The present inventors conducted intensive and thorough research into the development of a marker for predicting antibiotic therapy responsiveness in patients infected with nontuberculous mycobacteria (NTM) for which an objective and reliable diagnostic marker is difficult to develop, especially, Mycobacterium avium complex (MAC), which very commonly causes lung diseases in humans. As a result, 10 types of lipid metabolites that can predict antibiotic therapy responsiveness and treatment success probability in patients infected with non-tuberculous mycobacteria, with high reproducibility, and 40 types of lipid metabolites that can predict the success possibility for antibiotic therapy responses in infected patients according to patient characteristics such as sex and body mass index, high reproducibility were applied as markers, whereby the therapy responsiveness in patients infected with nontuberculous mycobacteria is determined to establish a patient-specific therapeutic strategy at an early stage, and thus can be advantageously used to significantly improve the survival rate of patients.

Description

Metabolic markers for predicting treatment response in patients infected with Mycobacterium avium complex

The present invention relates to a lipid metabolome marker for predicting treatment responsiveness of patients infected with Mycobacterium avium complex.

Mycobacterium includes not only species that cause serious diseases to humans and animals, such as tuberculosis, Mycobacterium bovis, and Mycobacterium leprae, but also species that are referred to as opportunistic infections, and About 72 species are known to date, including saprophytic species that can be seen in the natural environment, and among them, 25 species are known to be related to human diseases. These Mycobacterium genus are not easily dyed with commonly used staining solutions, but once dyed, they are also called acid-fast bacteria because they are not easily discolored even when treated with alcohol or hydrochloric acid.

Nontuberculous mycobacteria (NTM) means mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae. On the other hand, among non-tuberculous mycobacterium strains belonging to the Mycobacterium avium complex (MAC), about 180 or more strains that commonly cause lung diseases in humans have been officially identified. MAC mainly includes M. avium ( M. avium ) and M. intracellulare ( M. intracellulare ), and Mycobacterium abscessus ( MAB ) is mainly M. abscessus subspecies Absesu. ( M. abscessus subspecies abscessus ) and M. abscessus subspecies massiliense ( M. abscessus subspecies massiliense ). Recently, reports of lung infections caused by non-tuberculous mycobacteria are increasing worldwide, but there is a lack of biomarkers for distinguishing patients with non-tuberculous mycobacteria lung infections from healthy populations, or studies on the pathophysiology of the disease.

The present inventors studied patients infected with Nontuberculous mycobacteria (NTM), in particular, Mycobacterium avium complex (MAC), which causes lung diseases very common in humans, for which it is difficult to develop objective and reliable diagnostic markers. intensive research efforts were made to discover markers for predicting antibiotic treatment responsiveness. As a result, 10 types of lipid metabolites that can predict the antibiotic treatment responsiveness and treatment success possibility of patients infected with non-tuberculous mycobacteria with high reproducibility were discovered, and the possibility of antibiotic treatment response success of infected patients was analyzed by gender, body mass index, etc. According to the information, 40 types of lipid metabolites that can be predicted with high reproducibility were discovered.

Accordingly, an object of the present invention is to provide a composition for predicting the success or failure of antibiotic treatment response in patients infected with non-tuberculous mycobacteria.

Another object of the present invention is to provide a predictive composition for confirming the success or failure of antibiotic treatment response in patients infected with non-tuberculous mycobacteria according to information.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

Hereinafter, various embodiments described herein are described with reference to the drawings. In the following description, numerous specific details are set forth, such as specific forms, compositions and processes, etc., in order to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or with other known methods and forms. In other instances, well known processes and manufacturing techniques have not been described in specific detail in order not to unnecessarily obscure the present invention. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, form, composition or characteristic described in connection with the embodiment is included in one or more embodiments of the invention. Thus, the appearances of "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the invention. Additionally, particular features, forms, compositions, or properties may be combined in one or more embodiments in any suitable way.

Unless there is a specific definition within the present invention, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

According to one aspect of the present invention, the present invention is from the group consisting of Lysophosphatidylethanolamine (LPE), Phosphatidylcholine (PC), Sphingomyeline (SM) and triacylglycerol (TAG). Provided is a composition for predicting treatment responsiveness to antibiotics in patients infected with non-tuberculous mycobacteria, comprising an agent for measuring one or more selected metabolites as an active ingredient.

The present inventors studied patients infected with Nontuberculous mycobacteria (NTM), in particular, Mycobacterium avium complex (MAC), which causes lung diseases very common in humans, for which it is difficult to develop objective and reliable diagnostic markers. intensive research efforts were made to discover markers for predicting antibiotic treatment responsiveness. As a result, 10 types of lipid metabolites were discovered as diagnostic markers that can predict antibiotic treatment responsiveness and treatment success potential of patients infected with non-tuberculous mycobacteria with high reproducibility.

In the present specification, the term "non-tuberculosis mycobacteria" refers to acid-fast bacteria other than Mycobacterium tuberculosis, and specifically includes all mycobacteria that do not cause tuberculosis and leprosy. Anti-acid bacteria, unlike general bacteria, mean strains that do not dissolve and have the ability to withstand the addition of acid during the dyeing process. Mycobacterium tuberculosis is representative of these mycobacteria, and mycobacteria other than Mycobacterium tuberculosis are called nontuberculous mycobacteria (NTM), and new nontuberculous mycobacteria are discovered almost every year.

As used herein, the term “antibiotics” refers to antimicrobial substances used to prevent bacterial infections or treat bacterial diseases. It inhibits bacteria by killing or inhibiting their growth, and is an antibacterial drug used for the treatment and prevention of pathogenic bacterial infections. Antibacterial agents are commonly used as antibiotics in a broad sense, and include antimicrobial agents and antifungal agents. When antibiotics are used, they have the effect of killing bacteria or inhibiting their growth by pharmacological mechanisms. Some drugs are effective against microorganisms such as certain molds or protists, but not against viruses. In addition, antibiotics are classified into cell wall synthesis inhibitors, cell membrane disruptors, protein synthesis inhibitors, nucleic acid synthesis inhibitors, and folate synthesis inhibitors according to the mechanism of action and the action of the antibiotic.

Specifically, the antibiotics include, for example, penicillin G, amoxicillin, ampicillin, piperacillin, amoxicillin/clavulanicacid, ampicillin/sulbactam ( ampicillin/sulbactam), piperacillin/tazobactam, cefazolin, cephalexin, cefaclor, cefmetazole, cefotiam, cefuroxime (cefuroxime), cefotaxime, ceftriaxone, ceftazidime, cefepime, imipenem/cilastatin, meropenem, doripenem ), ertapenem, gentamicin, tobramycin, amikacin, tetracycline, doxycycline, minocycline, tigecycline ), erythromycin, clarithromycin, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin. However, it is not limited thereto.

As used herein, the term "prediction" refers to evaluating whether an object infected with a specific pathogen, for example, non-tuberculous mycobacteria, is responsive or resistant to antibiotic treatment based on a marker having a significant correlation with treatment responsiveness. means that

As used herein, the term “composition for prediction” refers to an integrated mixture including a means for measuring the concentration of lipid metabolites in order to predict whether or not a subject has antibiotic treatment responsiveness to non-tuberculosis mycobacterium infection, or It means a device, and can also be expressed as a “kit for prediction”. Since the composition for prediction of the present invention includes a means for measuring the metabolite discovered in the present invention, the term "composition for prediction" may also be expressed as a "device for quantification" of metabolites.

As used herein, the term "metabolite", also referred to as a metabolite or metabolite, is an intermediate or product of metabolism. These metabolites are fuel, structure, signal transduction, stimulatory and inhibitory effects on enzymes, their own catalytic activity (usually as cofactors for enzymes), defense, and interactions with other organisms (e.g., pigments, aromatic compounds). , pheromones). Primary metabolites are directly involved in normal growth, development and reproduction. Secondary metabolites are not directly involved in these processes, but usually have important ecological functions.

According to the present invention, the metabolite refers to a metabolite obtained from a sample of biological origin, that is, a biological sample, and the biological sample refers to a biological fluid, tissue or cell.

According to the present invention, the metabolite may be a metabolite obtained from a liquid sample derived from blood, specifically serum.

According to a specific embodiment of the present invention, the lysophosphatidylethanolamine is LPE (18:2).

According to a specific embodiment of the present invention, the phosphatidylcholine is PC 34:3 (16:1/18:2), PC 36:1 (18:0/18:1), PC 36:2 (18:0/18 :2), at least one phosphatidylcholine selected from the group consisting of PC 28:0 (14:0/14:0) and PC 30:0 (14:0/16:0).

According to a specific embodiment of the present invention, sphingomyelin is SM d36:2 (d18:1/18:1).

According to a specific embodiment of the present invention, triacylglycerols are TAG 55:7 (21:5/18:2/16:0), TAG 58:11 (22:6/20:5/16:0) and TAG and at least one triacylglycerol selected from the group consisting of 60:11 (22:6/20:4/18:1).

According to a specific embodiment of the present invention, if the concentration of the sphingomyelin before administration of the antibiotic is lower than the concentration measured after administration of the antibiotic, the patient infected with the non-tuberculosis mycobacteria is determined to have a therapeutic response to the antibiotic. .

The term “decreased or low concentration” used while referring to “sphingomyelin” in the composition of the present invention refers to a case where the concentration before administration of antibiotics is significantly lower than the concentration measured after administration of antibiotics, and specifically, the metabolic It means a decrease of about 5% or more, more specifically, a decrease of about 10% or more, and most specifically, a decrease of about 15% or more by comparing the concentration before and after antibiotic administration in the body, but the range outside this range does not exclude

As used herein, the term "therapeutic responsiveness" means that the survival rate, proliferation rate, activity, or pathogenicity of non-tuberculous mycobacteria is reduced to a clinically measurable extent compared to those not administered with antibiotics.

According to a specific embodiment of the present invention, when the concentration of the triacylglycerol before administration of the antibiotic is higher than the concentration measured after administration of the antibiotic, the patient infected with the non-tuberculous mycobacteria is determined to have a therapeutic response to the antibiotic.

The term "increase or high concentration" used while referring to "triacylglycerol" in the composition of the present invention refers to a case in which the concentration before administration of antibiotics in a patient is significantly higher than the concentration measured after administration of antibiotics. Specifically, The concentration of the metabolites before administration of antibiotics is increased by about 10% or more, more specifically by about 15% or more, more specifically by about 20% or more, and more specifically by about 25% or more compared to the concentration after administration of antibiotics. % or more increase, more specifically, it means an increase of about 30% or more, and most specifically, it means an increase of about 35% or more, but it does not exclude a range outside this range.

According to a specific embodiment of the present invention, the concentration of the phosphatidylcholine (PC 36:1 (18:0/18:0)) or PC 36:2 (18:0/18:2) before administration of antibiotics is measured after administration of antibiotics. If the concentration is lower than one concentration, it is determined that the patient infected with the non-tuberculous mycobacterium has a therapeutic response to antibiotics.

The term “decreased or low concentration” used while referring to “phosphatidylcholine (PC 36:1 (18:0/18:0))” in the composition of the present invention means that the concentration before administration of antibiotics is higher than the concentration measured after administration of antibiotics. It means a case that is relatively low, specifically, a decrease of about 5% or more, more specifically, a decrease of about 10% or more, more specifically, a decrease of about 15% or more compared to the concentration before and after antibiotic administration of the metabolite. It means, and most specifically, it means a case where it is reduced by about 20% or more, but it does not exclude a range outside this.

According to a specific embodiment of the present invention, when the concentration of the phosphatidylcholine (PC 34:3 (16:1/18:2)) before administration of antibiotics is higher than the concentration measured after administration of antibiotics, infection by the non-tuberculous mycobacteria The patient is determined to be therapeutically responsive to antibiotics.

The term “increase or increase in concentration” used while referring to “phosphatidylcholine (PC 34:3 (16:1/18:2))” in the composition of the present invention means that the concentration before antibiotic administration is higher than the concentration measured after administration of antibiotics. It means an increase of about 5% or more, more specifically, an increase of about 10% or more, more specifically, an increase of about 15% or more compared to the concentration of the metabolite before and after antibiotic administration. It means, and most specifically, it means the case of increasing by about 20% or more, but it does not exclude the range outside this.

According to a specific embodiment of the present invention, the lysophosphatidylethanolamine (LPE (18:2)), phosphatidylcholine (PC 28:0 (14:0/14:0)) or PC 30:0 (14:0/16 :0) If the concentration before administration of antibiotics is higher than the concentration measured after administration of antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have a therapeutic response to antibiotics.

The term “increase or high concentration” used while referring to “lysophosphatidylethanolamine” in the composition of the present invention refers to a case where the concentration before administration of antibiotics is significantly higher than the concentration measured after administration of antibiotics, and specifically, the metabolic An increase of about 10% or more, more specifically an increase of about 15% or more, more specifically an increase of about 20% or more, more specifically an increase of about 25% or more compared to the concentration before and after antibiotic administration of the body, More specifically, it means an increase of about 30% or more, and most specifically means an increase of about 35% or more, but it does not exclude a range outside this range.

According to a specific embodiment of the present invention, the measurement after administration of the antibiotic is performed 2 to 4 months after administration of the antibiotic. More specifically, it means after 70 days to 110 days, more specifically means after 80 days to 100 days, and most specifically means after about 90 days.

According to a specific embodiment of the present invention, the metabolite is whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum ), sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva ), peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid ), pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell, It is present in cell extracts and cerebrospinal fluid. Specifically, whole blood, plasma or serum may be pretreated to detect the metabolites. For example, it may include filtration, distillation, extraction, separation, concentration, inactivation of interfering components, addition of reagents, and the like. In addition, the metabolites may include substances produced by metabolism and metabolic processes or substances generated by chemical metabolism by biological enzymes and molecules.

According to a specific embodiment of the present invention, the non-tuberculous mycobacteria are Mycobacterium avium ( M. avium ), Mycobacterium abscessus ( M. abscessus ), Mycobacterium flavecens ( M. flavescence ), Mycobacterium africanum ( M. africanum ), Mycobacterium bovis ( M. bovis ), Mycobacterium chelone ( M. chelonae ), Mycobacterium cellatum ( M. celatum ), Mycobacterium Fortuitum ( M. fortuitum ), Mycobacterium Gordone ( M. gordonae ), Mycobacterium gastri ( M. gastri ), Mycobacterium hemophilum ( M. haemophilum ), Mycobacterium Cobacterium intracellular lare ( M. intracellulare ), Mycobacterium kansasii ( M. kansasii ), Mycobacterium malmoenseu ( M. malmoense ), Mycobacterium marinum ( M. marinum ), mycobac Therium suzulgai ( M. szulgai ), Mycobacterium terre ( M. terrae ), Mycobacterium scrofulaceum ( M. scrofulaceum ), Mycobacterium Ulceranseu ( M. ulcerans ), Mycobacterium It may be selected from the group consisting of Leeum simiae ( M. simiae ) and Mycobacterium xenopi ( M. xenopi ), but is not limited thereto.

According to the present invention, the non-tuberculous mycobacterial infectious disease includes all clinical symptoms caused by infection with the non-tuberculous mycobacterium, and the infectious disease is lung disease, lymphadenitis, skin, soft tissue, bone infection, or disseminated disease. diseases and the like.

According to another aspect of the present invention, the present invention measures one or more metabolites selected from the group consisting of Lysophosphatidylethanolamine, Phosphatidylcholine, Sphingomyeline and Triacylglycerol It provides an information providing method for predicting treatment responsiveness to antibiotics of patients infected with non-tuberculous mycobacteria, comprising the step of doing.

In the present invention, since the lipid metabolite, which is a measurement target of non-tuberculous mycobacteria, has already been described above, description thereof is omitted to avoid excessive redundancy.

According to a specific embodiment of the present invention, the step of measuring the concentration of the metabolite uses a quantitative device such as chromatography or mass spectrometry.

Chromatography used in the present invention includes high performance liquid chromatography (HPLC), liquid-solid chromatography (LSC), paper chromatography (PC), thin layer chromatography (Thin -Layer Chromatography (TLC), Gas-Solid Chromatography (GSC), Liquid-Liquid Chromatography (LLC), Foam Chromatography (FC), Emulsion Chromatography Chromatography (EC), Gas-Liquid Chromatography (GLC), Ion Chromatography (IC), Gel Filtration Chromatography (GFC) or Gel Permeation Chromatography (GLC) GPC), but is not limited thereto, and all quantitative chromatography commonly used in the art may be used.

In the present invention, the mass spectrometer may use a conventionally known mass spectrometer without particular limitation, but specifically, for example, a Fourier transform mass spectrometer (FTMS), a Maldi-TOF mass spectrometer (MALDI-TOF MS), It may be Q-TOF MS or LTQ-Orbitrap MS, but is not limited thereto.

According to another aspect of the present invention, the present invention is lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), sphingomyelin (SM) for predicting treatment responsiveness to antibiotics in patients infected by non-tuberculous mycobacteria and uses of triacylglycerols (TAGs).

According to another aspect of the present invention, the present invention provides lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (Sphingomyeline; SM) and triacylglycerol (Triacylglycerol; TAG) containing as an active ingredient an agent measuring one or more metabolites selected from the group consisting of antibiotics in patients infected with mycobacterium tuberculosis. A composition for

The present inventors studied patients infected with Nontuberculous mycobacteria (NTM), in particular, Mycobacterium avium complex (MAC), which causes lung diseases very common in humans, for which it is difficult to develop objective and reliable diagnostic markers. Research efforts were made to discover markers that could predict the success of antibiotic treatment. As a result, 40 types of lipid metabolites were discovered as diagnostic markers that can predict with high reproducibility the possibility of antibiotic treatment response success in patients infected with non-tuberculous mycobacteria according to patient characteristics such as gender and body mass index.

In the present specification, the term "non-tuberculosis mycobacteria" refers to acid-fast bacteria other than Mycobacterium tuberculosis, and specifically includes all mycobacteria that do not cause tuberculosis and leprosy. Anti-acid bacteria, unlike general bacteria, mean strains that do not dissolve and have the ability to withstand the addition of acid during the dyeing process. Mycobacterium tuberculosis is representative of these mycobacteria, and mycobacteria other than Mycobacterium tuberculosis are called nontuberculous mycobacteria (NTM), and new nontuberculous mycobacteria are discovered almost every year.

As used herein, the term “antibiotics” refers to antimicrobial substances used to prevent bacterial infections or treat bacterial diseases. It inhibits bacteria by killing or inhibiting their growth, and is an antibacterial drug used for the treatment and prevention of pathogenic bacterial infections. Antibacterial agents are commonly used as antibiotics in a broad sense, and include antimicrobial agents and antifungal agents. When antibiotics are used, they have the effect of killing bacteria or inhibiting their growth by pharmacological mechanisms. Some drugs are effective against microorganisms such as certain molds or protists, but not against viruses. In addition, antibiotics are classified into cell wall synthesis inhibitors, cell membrane disruptors, protein synthesis inhibitors, nucleic acid synthesis inhibitors, and folate synthesis inhibitors according to the mechanism of action and the action of the antibiotic.

Specifically, the antibiotics include, for example, penicillin G, amoxicillin, ampicillin, piperacillin, amoxicillin/clavulanicacid, ampicillin/sulbactam ( ampicillin/sulbactam), piperacillin/tazobactam, cefazolin, cephalexin, cefaclor, cefmetazole, cefotiam, cefuroxime (cefuroxime), cefotaxime, ceftriaxone, ceftazidime, cefepime, imipenem/cilastatin, meropenem, doripenem ), ertapenem, gentamicin, tobramycin, amikacin, tetracycline, doxycycline, minocycline, tigecycline ), erythromycin, clarithromycin, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin. However, it is not limited thereto.

As used herein, the term "prediction" refers to evaluating whether an object infected with a specific pathogen, for example, non-tuberculous mycobacteria, is responsive or resistant to antibiotic treatment based on a marker having a significant correlation with treatment responsiveness. means that

As used herein, the term “composition for prediction” refers to an integrated mixture including a means for measuring the concentration of lipid metabolites in order to predict whether or not a subject has antibiotic treatment responsiveness to non-tuberculosis mycobacterium infection, or It means a device, and can also be expressed as a “kit for prediction”. Since the composition for prediction of the present invention includes a means for measuring the metabolite discovered in the present invention, the term "composition for prediction" may also be expressed as a "device for quantification" of metabolites.

As used herein, the term "metabolite", also referred to as a metabolite or metabolite, is an intermediate or product of metabolism. These metabolites are fuel, structure, signal transduction, stimulatory and inhibitory effects on enzymes, their own catalytic activity (usually as cofactors for enzymes), defense, and interactions with other organisms (e.g., pigments, aromatic compounds). , pheromones). Primary metabolites are directly involved in normal growth, development and reproduction. Secondary metabolites are not directly involved in these processes, but usually have important ecological functions.

According to the present invention, the metabolite refers to a metabolite obtained from a sample of biological origin, that is, a biological sample, and the biological sample refers to a biological fluid, tissue or cell.

According to the present invention, the metabolite may be a metabolite obtained from a liquid sample derived from blood, specifically serum.

According to a specific embodiment of the present invention, the lysophosphatidylcholine is at least one lysophosphatidylcholine selected from the group consisting of LPC (20:3), LPC (14:0) and LPC (15:0).

According to a specific embodiment of the present invention, the lysophosphatidylethanolamine is at least one lysophosphatidylethanolamine selected from the group consisting of LPE (22:6) and LPE (20:4).

According to a specific embodiment of the present invention, the phosphatidylcholine is PC 28:0 (14:0/14:0), PC 33:2 (18:2/15:0), PC 34:3 (16:1/18 :2), PC 36:1(18:0/18:1), PC 36:3(16:0/20:3), PC 36:4(20:4/16:0), PC 28:0 (14:0/14:0), PC 30:0(14:0/16:0), PC 34:2(18:2/16:0), PC 36:2(18:0/18:2 ) and at least one phosphatidylcholine selected from the group consisting of PC 36:6 (14:0/22:6).

According to a specific embodiment of the present invention, the phosphatidylethanolamine is PE--NME 34:1 (18:1/16:0).

According to a specific embodiment of the present invention, the sphingomyelin is SM d40:2 (d18:2/22:0), SM d41:1 (d18:1/23:0), SM d34:1 (d18: 1/16:0), at least one sphingomyelin selected from the group consisting of SM d36:1 (d18:1/18:0)) and SM d35:1 (d18:1/17:0) .

According to a specific embodiment of the present invention, the triacylglycerol is TAG 55:7 (21:5/18:2/16:0), TAG 58:11 (22:6/20:5/16:0), and at least one triacylglycerol selected from the group consisting of TAG 60:11 (22:6/20:4/18:1) and TAG 60:12 (22:6/22:6/16:0).

According to a specific embodiment of the present invention, the lysophosphatidylcholine (LPC 18:0) and phosphatidylcholine (PC 28:0 (14:0/14:0)) in the patient infected with the non-tuberculous mycobacteria measured before antibiotic administration. , if the concentration of PC 36:1 (18:0/18:1) or PC 36:3 (16:0/20:3) is lower than the concentration measured in patients unresponsive to antibiotics, the non-tuberculosis Patients infected with mycobacteria are judged to have a therapeutic response to antibiotics.

The term “decreased or low concentration” used while referring to “lysophosphatidylcholine (LPC 18:0)” in the composition of the present invention means that the concentration of a patient with treatment responsiveness before administration of antibiotics is higher than the concentration measured in patients without treatment responsiveness. It means a significantly low case, specifically, a decrease of about 10% or more, more specifically, a decrease of about 20% or more compared to a patient with treatment responsiveness and a patient without treatment responsiveness in the concentration of the metabolite, Most specifically, it means a case of decreasing by about 30% or more, but it does not exclude a range outside this range.

As used herein, the term "therapeutic responsiveness" means that the survival rate, proliferation rate, activity, or pathogenicity of non-tuberculous mycobacteria is reduced to a clinically measurable extent compared to those not administered with antibiotics.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 33:2 (18:2/15:0)), PC 34:3 (16:1) in a patient infected with the non-tuberculous mycobacteria measured before antibiotic administration /18:2), sphingomyelin (SM d40:2 (d18:2/22:0)), or SM d41:1 (d18:1/23:0) concentrations in patients who do not show a therapeutic response to antibiotics If it is higher than the concentration measured in, it is determined that the patient infected with the non-tuberculous mycobacterium has a therapeutic response to antibiotics.

The term “increased or high concentration” used while referring to “phosphatidylcholine (PC 33:2 (18:2/15:0))” in the composition of the present invention refers to the concentration of a patient with treatment responsiveness prior to antibiotic administration. This means that the concentration of the metabolite is significantly higher than the concentration measured in patients without treatment, and specifically, the concentration of the metabolite is increased by about 5% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically An increase of 10% or more, more specifically, an increase of about 15% or more, and most specifically, an increase of about 20% or more, but a range outside this range is not excluded.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 28:0 (14:0/14:0 )) is lower than the concentration measured in a patient with no treatment response to antibiotics, the patient infected with the non-tuberculosis mycobacteria is determined to have treatment response to antibiotics.

In the present invention, the term “nodular bronchiectasis type” refers to bronchi in which multiple bronchiectasis in the center and small nodules and infiltrates around mainly invade the lingular segments of the right middle lobe and the left upper lobe, and nodules and infiltrates are observed on both sides of the lower lungs. means expansion. In the nodular bronchiectasis type, MAC is not always isolated in the sputum culture test and is intermittently positive, and even when cultured, the number of colonies is not large. In the United States, Japan, and domestic reports, it accounts for 50% of all MAC lung diseases, and the incidence rate is the same as or higher than that of the upper lobe cavity type.

Among the components of the present invention, the term “decreased or low concentration” used while referring to the “composition for prediction” refers to the concentration measured in patients with treatment responsiveness before antibiotic administration in patients with nodular bronchiectasis and the concentration measured in patients without treatment responsiveness. It means a significantly lower case, specifically, a decrease of about 10% or more, more specifically, a decrease of about 20% or more, more specifically, a decrease in the concentration of the metabolite compared to a patient with treatment responsiveness and a patient without treatment responsiveness. Specifically, it means a decrease of 30% or more, and most specifically means a case of a decrease of about 40% or more, but it does not exclude a range outside this range.

According to a specific embodiment of the present invention, the lysophosphatidylethanolamine (LPE (22:6)) or phosphatidylcholine in a patient infected with the non-tuberculous mycobacteria measured before antibiotic administration in a patient with an upper lobe cavity type (LPE (22:6)) If the concentration of (PC 36:4 (20:4/16:0)) is lower than the concentration measured in patients without treatment responsiveness to antibiotics, patients infected with the non-tuberculosis mycobacteria show better treatment responsiveness to antibiotics. judge that there is

In the present invention, the term “upper lobe cavity type” refers to a lung disease leading to death due to destruction of extensive lung parenchyma and respiratory failure. In chest radiography, upper lobe cavity and fibrosis-like lesions similar to pulmonary tuberculosis are observed, but the opacity is less, contact spread is more distinct, and lesions are less opaque than spread through the thin-walled cavity and bronchi surrounded by the lung parenchyma. It has more pronounced invasive features. It occurs frequently in middle-aged males with a long-term smoking and drinking history, and characteristically, most patients are accompanied by an underlying disease.

Among the components of the present invention, the term “decreased or low concentration” used while referring to the “composition for prediction” means that the concentration of a patient with a treatment response before administration of antibiotics in a patient with upper lobe cavity type is higher than the concentration measured in a patient without treatment response. It means a significantly low case, specifically, a decrease of about 10% or more, more specifically, a decrease of about 20% or more, more specifically, a decrease in the concentration of the metabolite compared to a patient with treatment responsiveness and a patient without treatment responsiveness. By means a reduction of 30% or more, and most specifically means a case of a decrease of about 40% or more, but does not exclude a range outside this range.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 33:2 (18:2/15 If the concentration of :0)) is higher than the concentration measured in a patient with no treatment response to antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have treatment response to antibiotics.

The term "increased or high concentration" used while referring to "composition for prediction" in the composition of the present invention refers to the concentration of a patient who has a treatment response before antibiotic administration in a patient who has converted from a nodular bronchiectasis type to an upper lobe cavity type. This means that the concentration of the metabolite is significantly higher than the concentration measured in patients without treatment, and specifically, the concentration of the metabolite is increased by about 5% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically It means an increase of 10% or more, more specifically an increase of about 15% or more, more specifically an increase of about 20% or more, and most specifically an increase of about 25% or more, but excluding the range outside this range It's not.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 33:2 (18: 2/15:0)), PC 34:3 (16:1/18:2), sphingomyelin (SM d40:2 (d18:2/22:0)) or SM d41:1 (d18:1 /23: 0) is higher than the concentration measured in patients without treatment responsiveness to antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have treatment responsiveness to antibiotics.

The term "increased or high concentration" used while referring to "composition for prediction" in the composition of the present invention refers to the concentration of patients infected with Mycobacterium avium bacteria and responding to treatment before antibiotic administration. is significantly higher than the concentration measured in patients without treatment responsiveness, specifically, the concentration of the metabolite is increased by about 5% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically As an increase of about 10% or more, more specifically, an increase of about 15% or more, more specifically, an increase of about 20% or more, and most specifically, an increase of about 25% or more, but It does not exclude scope.

According to a specific embodiment of the present invention, the lysophosphatidylethanolamine (LPE (20 If the concentration of :4)) is lower than the concentration measured in a patient with no treatment response to antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have treatment response to antibiotics.

Among the components of the present invention, the term "decreased or low concentration" used while referring to "composition for prediction" refers to the treatment response of a patient infected with Mycobacterium intracellulare bacteria prior to antibiotic administration. It means a case where the concentration is significantly lower than the concentration measured in a patient who is not responsive to treatment, and specifically, the concentration of the metabolite is reduced by about 5% or more compared to a patient who is responsive to treatment and a patient who is not responsive to treatment. Specifically, it means a decrease of about 10% or more, more specifically, a decrease of about 15% or more, and most specifically, a decrease of about 20% or more, but it does not exclude a range outside this range.

According to a specific embodiment of the present invention, the lysophosphatidylcholine (LPC 20:3), phosphatidylcholine (PC 36:3 (16:0/20: 3)), sphingomyelin (SM d34:1 (d18:1/16:0)) or SM d36:1 (d18:1/18:0) concentration measured in patients with no treatment response to antibiotics If the concentration is lower than one concentration, it is determined that the patient infected with the non-tuberculous mycobacterium has a therapeutic response to antibiotics.

Among the components of the present invention, the term “decreased or low concentration” used while referring to “composition for prediction” refers to a male patient infected with non-tuberculous mycobacteria whose concentration in a patient with treatment responsiveness before administration of antibiotics is not responsive to treatment. It means a case that is significantly lower than the concentration measured in, and specifically, the concentration of the metabolite is reduced by about 10% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically, by about 20% or more reduction, more specifically a reduction of about 30% or more, more specifically a reduction of about 40% or more, even more specifically a reduction of about 50% or more, and most specifically a case of about 60% or more reduction However, it does not exclude the scope outside of this.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 28:0 (14:0/14:0)), PC 30:0 (PC 28:0 (14:0/14:0)), PC 30:0 ( 14:0/16:0) or PC 36:1 (18:0/18:1) if the concentration is lower than the concentration measured in patients who do not respond to antibiotics, patients infected with the non-tuberculous mycobacteria is determined to be therapeutically responsive to antibiotics.

Among the components of the present invention, the term “decreased or low concentration” used while referring to the “composition for prediction” refers to a female patient infected with non-tuberculous mycobacteria whose concentration in a patient with treatment responsiveness before administration of antibiotics is not responsive to treatment. It means a case that is significantly lower than the concentration measured in, and specifically, the concentration of the metabolite is reduced by about 10% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically, by about 20% or more reduction, more specifically a reduction of about 30% or more, more specifically a reduction of about 40% or more, even more specifically a reduction of about 50% or more, and most specifically a case of about 60% or more reduction However, it does not exclude the scope outside of this.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 33:2 (18:2/15:0)) or sphingomyelin (PC 33:2 (18:2/15:0)) or sphingomyelin ( If the concentration of SM d35:1 (d18:1/17:0) is higher than the concentration measured in patients without treatment responsiveness to antibiotics, the patient infected with the non-tuberculous mycobacteria is considered to be responsive to antibiotic treatment. judge

Among the components of the present invention, the term "increased or high concentration" used while referring to "composition for prediction" refers to a female patient infected with non-tuberculous mycobacteria, in which the concentration of a patient with treatment responsiveness before administration of antibiotics is not responsive to treatment. It means a case that is significantly higher than the concentration measured in , and specifically, the concentration of the metabolite is increased by about 5% or more, more specifically, by about 10% or more compared to patients with treatment responsiveness and patients without treatment responsiveness. It means an increase, and most specifically means an increase of about 15% or more, but does not exclude a range outside this range.

According to a specific embodiment of the present invention, the sphingomyelin (SM d35: 1 (d18) in a patient infected with the non-tuberculous mycobacteria measured before antibiotic administration in a patient with a low body mass index :1/17:0)), triacylglycerol (TAG 55:7 (21:5/18:2/16:0)), TAG 58:11 (22:6/20:5/16:0), Concentrations of TAG 60:11 (22:6/20:4/18:1) or TAG 60:12 (22:6/22:6/16:0) measured in patients not responding to treatment with antibiotics If it is higher than that, it is determined that the patient infected with the non-tuberculous mycobacterium has a therapeutic response to antibiotics.

Among the components of the present invention, the term “increase or increase in concentration” used while referring to the “composition for prediction” refers to the concentration of a patient with a low body mass index in a patient who is responsive to treatment before antibiotic administration. It means a case that is significantly higher than the concentration measured in patients who are not responsive, specifically, the concentration of the metabolite is increased by about 10% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically An increase of about 20% or more, more specifically an increase of about 30% or more, more specifically an increase of about 40% or more, even more specifically an increase of about 50% or more, and most specifically an increase of about 60% or more It means a case of increasing, but does not exclude a range outside of this.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 33:2 (18:2/ 15:0)), PC 34:2 (18:2/16:0), PC 34:3 (16:1/18:2) or PC 36:2 (18:0/18:2) If the concentration is higher than the concentration measured in patients without treatment responsiveness to antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have treatment responsiveness to antibiotics.

The term "increased or high concentration" used while referring to "composition for prediction" in the composition of the present invention refers to the concentration of a patient with a normal body mass index before administration of antibiotics in a patient who is responsive to treatment. It means a case that is significantly higher than the concentration measured in patients who are not responsive, specifically, the concentration of the metabolite is increased by about 5% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically An increase of about 10% or more, more specifically, an increase of about 15% or more, and most specifically, an increase of about 20% or more, but a range outside this range is not excluded.

According to a specific embodiment of the present invention, the phosphatidylcholine (PC 36: 1 (18: 0/18: 1 )) or phosphatidylethanolamine (PE--NME 34: 1 (18: 1/16: 0)), when the concentration is lower than the concentration measured in patients not responsive to antibiotics, Infected patients are judged to have a therapeutic response to antibiotics.

Among the components of the present invention, the term "decreased or low concentration" used while referring to "composition for prediction" refers to the concentration of a patient with a normal body mass index before administration of antibiotics in a patient who is responsive to treatment. It means a case that is significantly lower than the concentration measured in patients who are not responsive, specifically, the concentration of the metabolite is reduced by about 5% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically A decrease of about 10% or more, more specifically, a decrease of about 15% or more, and most specifically, a decrease of about 20% or more, but a range outside this range is not excluded.

According to a specific embodiment of the present invention, the lysophosphatidylcholine (LPC 14:0), LPC ( 15:0) or phosphatidylcholine (PC 36:6 (14:0/22:6)), if the concentration is lower than the concentration measured in patients unresponsive to antibiotics, patients infected with the non-tuberculous mycobacterium Determined to be therapeutically responsive to antibiotics.

Among the components of the present invention, the term “decreased or low concentration” used while referring to “composition for prediction” refers to the concentration of a patient with a high body mass index (fat) who is responsive to treatment prior to antibiotic administration. It means a case that is significantly lower than the concentration measured in patients who are not responsive, specifically, the concentration of the metabolite is reduced by about 15% or more compared to patients with treatment responsiveness and patients without treatment responsiveness, more specifically Reduction of about 30% or more, more specifically, reduction of about 45% or more, more specifically, reduction of about 60% or more, and most specifically, reduction of about 75% or more, but the range outside this range does not exclude

According to a specific embodiment of the present invention, the body mass index is low for patients with a body mass index of less than 18.5, normal for patients with a body mass index of 18.5 or more and less than 23, and high for patients with a body mass index of 23 or more.

According to a specific embodiment of the present invention, the metabolite is whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum ), sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva ), peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid ), pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell, It is present in cell extracts and cerebrospinal fluid. Specifically, it may be serum, but is not limited thereto.

Specifically, whole blood, plasma or serum may be pretreated to detect the metabolites. For example, it may include filtration, distillation, extraction, separation, concentration, inactivation of interfering components, addition of reagents, and the like. In addition, the metabolites may include substances produced by metabolism and metabolic processes or substances generated by chemical metabolism by biological enzymes and molecules.

According to a specific embodiment of the present invention, the non-tuberculous mycobacteria are Mycobacterium avium ( M. avium ), Mycobacterium abscessus ( M. abscessus ), Mycobacterium flavecens ( M. flavescence ), Mycobacterium africanum ( M. africanum ), Mycobacterium bovis ( M. bovis ), Mycobacterium chelone ( M. chelonae ), Mycobacterium cellatum ( M. celatum ), Mycobacterium Fortuitum ( M. fortuitum ), Mycobacterium Gordone ( M. gordonae ), Mycobacterium gastri ( M. gastri ), Mycobacterium hemophilum ( M. haemophilum ), Mycobacterium Cobacterium intracellular lare ( M. intracellulare ), Mycobacterium kansasii ( M. kansasii ), Mycobacterium malmoenseu ( M. malmoense ), Mycobacterium marinum ( M. marinum ), mycobac Therium suzulgai ( M. szulgai ), Mycobacterium terre ( M. terrae ), Mycobacterium scrofulaceum ( M. scrofulaceum ), Mycobacterium Ulceranseu ( M. ulcerans ), Mycobacterium It may be selected from the group consisting of Leeum simiae ( M. simiae ) and Mycobacterium xenopi ( M. xenopi ), but is not limited thereto.

According to the present invention, the non-tuberculous mycobacterial infectious disease includes all clinical symptoms caused by infection with the non-tuberculous mycobacterium, and the infectious disease is lung disease, lymphadenitis, skin, soft tissue, bone infection, or disseminated disease. disease may include

According to another aspect of the present invention, Lysophosphatidylcholine, Lysophosphatidylethanolamine, Phosphatidylcholine, Phosphatidylethanolamine, Sphingomyeline and Triacylglycerol Provided is an information providing method for predicting treatment responsiveness of a patient infected with non-tuberculous mycobacteria, comprising the step of measuring one or more metabolites selected from the group consisting of.

In the present invention, since the lipid metabolite, which is a measurement target of non-tuberculous mycobacteria, has already been described above, description thereof is omitted to avoid excessive redundancy.

According to a specific embodiment of the present invention, the step of measuring the concentration of the metabolite uses a quantitative device such as chromatography or mass spectrometry.

Chromatography used in the present invention includes high performance liquid chromatography (HPLC), liquid-solid chromatography (LSC), paper chromatography (PC), thin layer chromatography (Thin -Layer Chromatography (TLC), Gas-Solid Chromatography (GSC), Liquid-Liquid Chromatography (LLC), Foam Chromatography (FC), Emulsion Chromatography Chromatography (EC), Gas-Liquid Chromatography (GLC), Ion Chromatography (IC), Gel Filtration Chromatography (GFC) or Gel Permeation Chromatography (GLC) GPC), but is not limited thereto, and all quantitative chromatography commonly used in the art may be used.

In the present invention, the mass spectrometer may use a conventionally known mass spectrometer without particular limitation, but specifically, for example, a Fourier transform mass spectrometer (FTMS), a Maldi-TOF mass spectrometer (MALDI-TOF MS), It may be Q-TOF MS or LTQ-Orbitrap MS, but is not limited thereto.

According to another aspect of the present invention, the present invention is lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine ( PE), sphingomyelin (SM) and triacylglycerol (TAG).

The present invention predicts the success of antibiotic treatment of infectious diseases with high accuracy by using the metabolites of non-tuberculous mycobacterium (NTM), especially Mycobacterium avium complex (MAC), which lacks objective and reliable diagnostic markers. It can be usefully used to determine the treatment responsiveness of patients infected with non-tuberculous mycobacteria by applying it as a marker that The present invention relates to non-tuberculosis mycobacterium (NTM), in particular Mycobacterium avium complex (MAC), which has no objective and highly reliable biomarker for the course of disease progression, and specific lipid metabolites such as gender, body mass index, etc. Significantly improved the survival rate of patients by determining the treatment responsiveness of patients infected with non-tuberculous mycobacteria by establishing a patient-specific treatment strategy at an early stage by applying markers that predict the success of antibiotic treatment according to patient characteristics with high accuracy It can be useful to do.

Figure 1a is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing expression concentration levels of phosphatidylcholine (PC 34:3 (16:1/18:2)).

Figure 1b is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing expression concentration levels of phosphatidylcholine (PC 36:1 (18:0/18:0)).

Figure 1c is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing expression concentration levels of phosphatidylcholine (PC 36:2 (18:0/18:2)).

Figure 1d is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. Sphingomyeline (SM d36: 2 (d18: 1/18: 1)) shows a graph comparing the expression concentration levels.

Figure 1e is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing the expression concentration level of triacylglycerol (TAG 55:7 (21:5/18:2/16:0)).

Figure 1f is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing the expression concentration level of triacylglycerol (TAG 58:11 (22:6/20:5/16:0)).

Figure 1g is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing the expression concentration level of triacylglycerol (TAG 60:11 (22:6/20:4/18:1)).

Figure 2a is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing the expression concentration level of Lysophosphatidylethanolamine (LPE (18:2)).

Figure 2b is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing expression concentration levels of phosphatidylcholine (PC 28:0 (14:0/14:0)).

Figure 2c is before antibiotic treatment (Tx0) and 3 months after treatment (Tx3) in serum samples from patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing expression concentration levels of phosphatidylcholine (PC 30:0 (14:0/16:0)).

Figure 3a shows Lysophosphatidylcholine in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in patients with Mycobacterium avium complex (MAC) infected lung disease in one embodiment of the present invention ; LPC 20: 3) shows a graph comparing the concentration and expression level.

Figure 3b is a Mycobacterium avium complex (MAC) infection in an embodiment of the present invention in patients with lung disease before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine; It shows a graph comparing the concentration expression level of PC 28:0 (14:0/14:0)).

Figure 3c is a Mycobacterium avium complex (MAC) infection in lung disease patients in one embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine; It shows a graph comparing the concentration and expression level of PC 33:2 (18:2/15:0)).

Figure 3d is a Mycobacterium avium complex (MAC) infection in an embodiment of the present invention in patients with lung disease before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine; It shows a graph comparing the concentration and expression level of PC 34:3 (16:1/18:2)).

Figure 3e is a Mycobacterium avium complex (MAC) infection in lung disease patients in one embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine; It shows a graph comparing the concentration and expression level of PC 36:1 (18:0/18:1)).

Figure 3f is a Mycobacterium avium complex (MAC) infected lung disease patient in one embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine; It shows a graph comparing the concentration and expression level of PC 36:3 (16:0/20:3)).

Figure 3g is a Mycobacterium avium complex (MAC) infected lung disease patient in one embodiment of the present invention before antibiotic treatment (Tx0) sphingomyelin in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) (Sphingomyeline; SM d40:2 (d18:2/22:0)) shows a graph comparing the concentration and expression level.

Figure 3h is a Mycobacterium avium complex (MAC) infection lung disease patient before antibiotic treatment (Tx0) Sphingomyelin in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) in one embodiment of the present invention (Sphingomyeline; SM d41: 1 (d18: 1/23: 0)) shows a graph comparing the concentration and expression level.

Figure 4 is a nodular bronchiectatic form (Phosphatidylcholine; PC 28: PC 28: 0 (14:0/14:0)) shows a graph comparing expression levels.

Figure 5a is a graph of lysophosphatidylethanolamine (Lysophosphatidylethanolamine; lysophosphatidylethanolamine; It shows a graph comparing the concentration and expression level of LPE (22:6)).

Figure 5b is a phosphatidylcholine (PC 36) in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in patients with upper lobe cavity type infection in one embodiment of the present invention: 4 (20:4/16:0)) shows a graph comparing the concentration and expression level.

6 is a graph of phosphatidylcholine (PC 33) in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in patients who have converted from nodular bronchiectasis type to upper lobe cavity type in one embodiment of the present invention. :2 (18:2/15:0)) shows a graph comparing the concentration and expression level.

Figure 7a is a Mycobacterium avium in one embodiment of the present invention ( Mycobacterium avium ) In patients infected by the bacteria, phosphatidylcholine in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) ; It shows a graph comparing the concentration and expression level of PC 33:2 (18:2/15:0)).

Figure 7b is a Mycobacterium avium in one embodiment of the present invention ( Mycobacterium avium ) In patients infected by the bacteria, phosphatidylcholine in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) ; It shows a graph comparing the concentration and expression level of PC 34:3 (16:1/18:2)).

Figure 7c is in one embodiment of the present invention, Mycobacterium avium ( Mycobacterium avium ) Sphingomyces in the serum of a patient infected by the bacteria before antibiotic treatment (Tx0) of a patient who will succeed and a patient who will fail before antibiotic treatment (Tx0) It shows a graph comparing the concentration and expression level of elin (Sphingomyeline; SM d40:2 (d18:2/22:0)).

Figure 7d is a Mycobacterium avium in one embodiment of the present invention ( Mycobacterium avium ) Sphingomyces in the serum of patients infected with bacteria before antibiotic treatment (Tx0) of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) It shows a graph comparing the concentration and expression level of elin (Sphingomyeline; SM d41: 1 (d18: 1/23: 0)).

Figure 8 is a lysophosphatidyl serum in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in patients infected by Mycobacterium intracellulare in one embodiment of the present invention It shows a graph comparing the concentration and expression level of ethanolamine (Lysophosphatidylethanolamine; LPE (20:4)). Figure 7d shows sphingomyces in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in male patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention It shows a graph comparing the concentration and expression level of elin (Sphingomyeline; SM d36: 1 (d18: 1/18: 0)).

Figure 9a is a Mycobacterium avium complex (MAC) infection in male patients with lung disease in one embodiment of the present invention before antibiotic treatment (Tx0) Lysophosphatidylcholine in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) It shows a graph comparing the concentration and expression level of Lysophosphatidylcholine; LPC 20:3).

Figure 9b is a Mycobacterium avium complex (MAC) infection in male patients with lung disease in one embodiment of the present invention before antibiotic treatment (Tx0) Phosphatidylcholine in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) ; It shows a graph comparing the concentration and expression level of PC 36:3 (16:0/20:3)).

Figure 9c shows sphingomyces in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in male patients with Mycobacterium avium complex (MAC) infected lung disease in one embodiment of the present invention It shows a graph comparing the concentration and expression level of elin (Sphingomyeline; SM d34: 1 (d18: 1/16: 0)).

Figure 10a is a Mycobacterium avium complex (MAC) infection in a female patient with lung disease in an embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Phosphatidylcholine) ; It shows a graph comparing the concentration and expression level of PC 28:0 (14:0/14:0)).

Figure 10b is a Mycobacterium avium complex (MAC) infection in a female patient with lung disease in an embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine) ; It shows a graph comparing the concentration and expression level of PC 30:0 (14:0/16:0)).

Figure 10c is a Mycobacterium avium complex (MAC) infection in a female patient with lung disease in an embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibiotic treatment (Tx0) Phosphatidylcholine ; It shows a graph comparing the concentration and expression level of PC 33:2 (18:2/15:0)).

Figure 10d is a Mycobacterium avium complex (MAC) infection in a female patient with lung disease in an embodiment of the present invention before antibiotic treatment (Tx0) in the serum of patients who will succeed and patients who will fail before antibacterial phosphatidylcholine (Phosphatidylcholine) ; It shows a graph comparing the concentration and expression level of PC 36:1 (18:0/18:1)).

Figure 10e shows sphingomyces in the serum of patients who will succeed before antibiotic treatment (Tx0) and patients who will fail before antibiotic treatment (Tx0) in female patients with Mycobacterium avium complex (MAC)-infected lung disease in one embodiment of the present invention. It shows a graph comparing the concentration and expression level of elin (Sphingomyeline; SM d35: 1 (d18: 1/17: 0)).

Figure 11a is a patient with a low body mass index (Body mass index) infected with Mycobacterium avium complex (MAC) in one embodiment of the present invention, before antibiotic treatment (Tx0) and a patient who will succeed before antibiotic treatment It shows a graph comparing the concentration and expression levels of sphingomyeline (SM d35:1 (d18:1/17:0)) in the serum of patients to fail.

Figure 11b is a patient with a low body mass index (Body mass index) infected with Mycobacterium avium complex (MAC) in an embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before the infection It shows a graph comparing the concentration and expression level of triacylglycerol (TAG 55:7 (21:5/18:2/16:0)) in the serum of patients who will fail.

Figure 11c is a patient with a low body mass index (Body mass index) infected with Mycobacterium avium complex (MAC) in an embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before the infection It shows a graph comparing the concentration and expression levels of triacylglycerol (TAG 58:11 (22:6/20:5/16:0)) in the serum of patients to fail.

Figure 11d is a patient with a low body mass index (Body mass index) infected with Mycobacterium avium complex (MAC) in one embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before the infection It shows a graph comparing the concentration and expression levels of triacylglycerol (TAG 60:11 (22:6/20:4/18:1)) in the serum of patients who will fail.

Figure 11e is a patient with a low body mass index (Body mass index) infected with Mycobacterium avium complex (MAC) in an embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before antibiotic treatment It shows a graph comparing the concentration and expression levels of triacylglycerol (TAG 60:12 (22:6/22:6/16:0)) in the serum of patients to fail.

12a is a diagram of a patient with a normal Mycobacterium avium complex (MAC) infected body mass index before antibiotic treatment (Tx0) and a patient who will succeed before antibiotic treatment (Tx0) in one embodiment of the present invention. It shows a graph comparing the concentration and expression level of phosphatidylcholine (PC 33:2 (18:2/15:0)) in the serum of patients who will fail.

Figure 12b is a patient with a normal Mycobacterium avium complex (MAC) infected body mass index (Body mass index) before antibiotic treatment (Tx0) in one embodiment of the present invention, and a patient who will succeed before the infection. It shows a graph comparing the concentration and expression level of phosphatidylcholine (PC 34:2 (18:2/16:0)) in the serum of patients who will fail.

Figure 12c is a patient with a normal body mass index infected with Mycobacterium avium complex (MAC) in an embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before the infection. It shows a graph comparing the concentration and expression levels of phosphatidylcholine (PC 34:3 (16:1/18:2)) in serum of patients who will fail.

12d is a diagram of a patient with a normal body mass index infected with Mycobacterium avium complex (MAC) in an embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before antibiotic treatment (Tx0) It shows a graph comparing the concentration and expression levels of phosphatidylcholine (PC 36:1 (18:0/18:1)) in the serum of patients who will fail.

Figure 12e is a patient with a normal Mycobacterium avium complex (MAC) infected body mass index (Body mass index) before antibiotic treatment (Tx0) in one embodiment of the present invention, and a patient who will succeed before the infection. It shows a graph comparing the concentration and expression levels of phosphatidylcholine (PC 36:2 (18:0/18:2)) in the serum of patients who will fail.

Figure 12f is a patient with a normal body mass index infected with Mycobacterium avium complex (MAC) before antibiotic treatment (Tx0) in an embodiment of the present invention and a patient who will succeed before the infection. It shows a graph comparing the concentration and expression levels of phosphatidylethanolamine (PE--NME 34:1 (18:1/16:0)) in the serum of patients to fail.

Figure 13a is a patient who will succeed before antibiotic treatment (Tx0) before antibiotic treatment in a patient with a high body mass index (fat) infected with Mycobacterium avium complex (MAC) in one embodiment of the present invention It shows a graph comparing the concentration and expression level of Lysophosphatidylcholine (LPC 14:0) in the serum of patients to fail.

Figure 13b is a Mycobacterium avium complex (MAC) infected patient with a high body mass index (fat) before antibiotic treatment (Tx0) in one embodiment of the present invention, and a patient who will succeed before the infection. It shows a graph comparing the concentration and expression level of Lysophosphatidylcholine (LPC 15:0) in the serum of patients who will fail.

Figure 13c is a Mycobacterium avium complex (MAC) infected patient with a high body mass index (fat) in one embodiment of the present invention before antibiotic treatment (Tx0) and a patient who will succeed before antibiotic treatment (Tx0) It shows a graph comparing the concentration and expression levels of phosphatidylcholine (PC 36:6 (14:0/22:6)) in the serum of patients who will fail.

The present invention is an infectious disease caused by Nontuberculous mycobacteria (NTM), in particular, Mycobacterium avium complex (MAC), which causes lung diseases very commonly in humans, for which it is difficult to develop objective and reliable diagnostic markers. A study was conducted to predict the responsiveness of antibiotic treatment in patients of . As a result, 10 types of lipid metabolites that can predict antibiotic treatment responsiveness and treatment success probability of patients infected with non-tuberculous mycobacteria with high reproducibility, and the possibility of antibiotic treatment response success of infected patients according to patient characteristics such as gender and body mass index. Accordingly, 40 lipid metabolites that can be predicted with high reproducibility were discovered as markers. In this way, it is possible to establish a patient-specific treatment strategy early by determining the treatment responsiveness of patients infected with mycobacterium tuberculosis.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

Example

[Experimental Example 1] Sample collection of MAC infected patients

Patients infected with Mycobacterium avium complex (avium: 80, intracellulare: 65, total 145) collected from Seoul Samsung Hospital for about 6 years from January 2012 to August 2016 145 serum samples before antibiotic treatment (Tx0) and 145 serum samples after 3 months of antibiotic treatment (Tx3) were prepared.

[Experimental Example 2] Pre-treatment of the sample

First, 300 μl chloroform and 150 μl methanol (chloroform-methanol, 2:1, v/v, 4° C.) were added to the serum sample (50 μl) obtained in Experimental Example 1 and mixed for 30 seconds. 150 μl water was added thereto, mixed for 30 seconds, put into ICE, and left for 10 minutes to extract. Thereafter, after centrifugation at 13,000 rpm, 4 ° C. for 10 minutes using a centrifuge, the lower layer (200 μl) was separated and dried using a speed vacuum (full vacuum, no temp, 1-2 hours) to obtain the following Stored at -20 °C until metabolome analysis. For mass spectrometry analysis, the dried sample was re-dissolved in 200 μl of isopropanol:acetonitrile:water (2:1:1, v/v), and then filtered to remove possible impurities. Analysis was performed after filtering using a filter tube (Costar 8169). As machine quality control (MQC), human serum samples purchased to check the MS/MS device status are used as samples for mechanical quality control (MQC) in the same pre-processing method as patient serum samples, per batch. Six replicates were analyzed. For sample quality control (SQC), in order to compare differences between samples in each batch, 10 μl per sample was collected and sample quality control was prepared and analyzed 6 times per batch.

[Experimental Example 3] Metabolome analysis through UHPLC-MS (Q-Exactive Orbitrap Plus)

In order to analyze lipid metabolites of analysis samples isolated from serum, analysis was performed using chromatography-tandem mass spectrometry (UHPLC-MS). The equipment used was Thermo Scientific's Ultimate 3000RS pump UHPLC and Q-Exactive Orbitrap Plus MS. Lipid metabolites were separated by gradient elution at 35°C using an Acquity UPLC BEH C18 (2.1 x 100 mm, 1.7 μm, Waters) column as chromatographic conditions for hydrophilic interaction. As mobile phase, (A) 10mM Ammonium formate in 50% ACN + 0.1% Formic acid (v/v) and (B) 2mM Ammonium formate in ACN/IPA/Water 10:88:2 + 0.02% Formic acid (v/v) was used, and the gradient elution of the next mobile phase was performed in the same manner as in Table 1 below with a total analysis time of 28 minutes.

Electrospray Ionization (ESI) was performed with positive and negative two modes of ionization, and the full scan mass range was 250-1200 m/z with a resolution of 70,000 and automatic gain control. (Automatic gain control, AGC) The target was 1x10 ⁶ ion and the maximum injection time (IT) was analyzed at 100ms. The collision energy (CE) was 20, 30, and 40, the source ionization spray voltage was 3.0 kV, and the capillary temperature was 370 °C. For the results obtained through the analysis, raw data were calculated through Thermo Scientific's analysis software (Compound Discoverer), and lipid metabolites with high significance (p-value <0.05) were calculated.

time (minutes)	Mobile phase A (%)	Mobile phase B (%)	Flow rate (mL/min)
0	65	35	0.30
4	40	60	0.30
12	15	85	0.30
21	0	100	0.30
24	0	100	0.30
28	65	35	0.30

[Experimental Example 4] Results of metabolome analysis in serum samples of non-tuberculous mycobacteria infected patients

Paired with Metaboanalyst (statistics site), Compound Discoverer of Thermofisher ^TM , and SPSS statistical program using the following statistical test method to compare lipid metabolite concentrations in MAC-infected patients before antibiotic treatment (Tx0) and after 3 months of treatment (Tx3) Lipid metabolites with high significance (p-value<0.05) or high probability (p-value<0.09) between groups were calculated through a t-test test, and the Mycobacterium avium complex before treatment was calculated using the results. (MAC) Total lipid metabolites that can distinguish whether treatment is successful or not, including 7 types in the successful patient group and 3 types in the unsuccessful patient group among patients with infectious lung disease and 3 months after treatment Ten species (p-value <0.05) were selected based on each p-value and the fold change value of the expression level before and after 3 months of treatment, and the results are shown in Table 2 and Figures 1a to 2c. . However, in FIGS. 1a to 2c, MAC-infected patients before treatment (Tx0) show the expression levels of each metabolite in serum samples from 145 patients, and after 3 months of treatment (Tx3), mycobacteria after 3 months of starting antibiotic treatment The expression level of each metabolite in serum samples from 145 patients infected with the rium avium complex (MAC) was shown. In addition, in the significance paired t-test, *P<0.05;**P<0.01;***P<0.001 means.

Lipid metabolites that can predict the success of Gyuneumjeon among MAC patients
Metabolite types (Compounds)	Significance (p-value) Success	FC (Tx3/Tx0) Success	Significance (p-value) Failure	FC (Tx3/Tx0) Failure
PC 34:3 (16:1/18:2)	<0.001	0.81	0.89	1.00
PC 36:1 (18:0/18:1)	<0.001	1.18	0.12	1.10
PC 36:2 (18:0/18:2)	0.02	1.11	0.15	1.06
SM d36:2 (d18:1/18:1)	<0.001	1.11	0.09	1.11
TAG 55:7 (21:5/18:2/16:0)	0.003	0.73	0.55	0.89
TAG 58:11(22:6/20:5/16:0)	0.07	0.68	0.48	1.18
TAG 60:11 (22:6/20:4/18:1)	0.003	0.70	0.89	0.90
Lipid metabolites that can predict failure of gyneumjeon in MAC patients
LPE 18:2	0.42	0.90	0.02	0.83
PC 28:0 (14:0/14:0)	0.33	1.00	0.001	0.66
PC 30:0 (14:0/16:0)	0.052	0.87	<0.001	0.74

[Experimental Example 5] Sample collection at the time point before treatment (Tx0) of patients with MAC infection

From January 2012 to August 2016, serum samples before treatment (Tx0) of 145 patients with Mycobacterium avium complex collected at Seoul Samsung Hospital for about 6 years were treated with antibiotics 3 After 3 months (Tx3), 97 patients who are likely to succeed in Gyuneumjeon and 48 patients who are likely to fail were prepared.

[Experimental Example 6] Among patients with MAC infection, nodular bronchiectatic form (NB) and upper lobe cavitary form (UC) and patient samples converted from NB to UC by type of lung disease were collected

Serum samples from 145 patients infected with the Mycobacterium avium complex collected at Samsung Hospital in Seoul for about 6 years from January 2012 to August 2016 were evaluated for bronchiectasis (Nodular bronchiectatic) according to the type of lung disease. NB), 31 patients with upper lobe cavity type (UC), and 31 patients with bronchiectasis converted to upper lobe cavity type.

[Experimental Example 7] Etiology of infectious bacteria in patients infected with MAC ( M.avium & M.intracellulare ) sample collection

Extracted from 145 serum samples before antibiotic treatment (Tx0) of Mycobacterium avium complex infected patients collected at Seoul Samsung Hospital for about 6 years from January 2012 to August 2016 prepared by

[Experimental Example 8] Sample collection according to sex (Men & Women) of MAC infected patients

From January 2012 to August 2016, 58 male patients out of 145 serum samples collected before antibiotic treatment (Tx0) of patients with Mycobacterium avium complex infection collected at Seoul Samsung Hospital for about 6 years. 80 male and female patients were extracted and prepared.

[Experimental Example 9] Sample collection according to BMI (Body Mass Index) index of MAC infected patients

Extracted from 145 serum samples before antibiotic treatment (Tx0) of Mycobacterium avium complex infected patients collected at Seoul Samsung Hospital for about 6 years from January 2012 to August 2016 prepared by

[Experimental Example 10] Pre-treatment of the sample

First, 300 μl chloroform and 150 μl methanol (chloroform-methanol, 2:1, v/v, 4° C.) were added to the serum samples (50 μl) obtained in Experimental Examples 1 to 5 and mixed for 30 seconds. 150 μl of water was added thereto, mixed for 30 seconds, put into ICE, and left for 10 minutes to extract. Then, after centrifugation at 13,000 rpm, 4 ℃ for 10 minutes using a centrifuge, 200 μl of the lower layer was separated and dried using a speed vacuum (full vacuum, no temp, 1-2 hours) to obtain the following metabolites Stored at -20 °C until analysis. For mass spectrometry analysis, the dried sample was re-dissolved in 200 μl isopropanol:acetonitrile:water (2:1:1, v/v) and filtered to remove possible impurities. After filtering using a filter tube (Costar 8169), analysis was performed. As Machinery Quality Control (MQC), it is repeated 6 times per batch using healthy human serum as a sample for Machinery Quality Control (MQC) as a pre-processing method like serum sample to check the MS/MS instrument condition. analyzed. For sample quality control (SQC), in order to compare differences between samples in each batch, 10 μl per sample was collected and sample quality control was prepared and analyzed 6 times per batch.

[Experimental Example 11] Metabolome analysis through UHPLC-MS (Q-Exactive Orbitrap Plus)

In order to analyze lipid metabolites in the analysis sample treated with serum, analysis was performed using chromatography-tandem mass spectrometry (UHPLC-MS). The equipment used was Thermo Scientific's Ultimate 3000RS pump UHPLC and Q-Exactive Orbitrap Plus MS. As chromatographic conditions for hydrophilic interaction, lipid metabolites were separated using an Acquity UPLC BEH C18 (2.1 x 100 mm, 1.7 μm, Waters) column using gradient elution at 35 °C. The first mobile phase includes (A) 10mM Ammonium formate in 50% ACN + 0.1% Formic acid (v/v) and (B) 2mM Ammonium formate in ACN/IPA/Water 10:88:2 + 0.02% Formic acid (v/v). v) was used, and the gradient elution of the next mobile phase was performed in the same manner as in Table 1 below with a total analysis time of 28 minutes. Electrospray Ionization (ESI) was performed in two modes of ionization, positive and negative, and the full scan mass range was 250-1200 m/z with 70,000 resolution. It was used, and the automatic gain control (AGC) target was analyzed with 1x10 ⁶ ions and the maximum injection time (Injection time, IT) was 100 ms. The collision energy (CE) was 20, 30, and 40, the source ionization spray voltage was 3.0 kV, and the capillary temperature was 370 °C. For the results obtained through the analysis, raw data were calculated through Thermo Scientific's analysis software (Compound Discoverer), and lipid metabolites with high significance (p-value <0.05) were calculated.

time (minutes)	Mobile phase A (%)	Mobile phase B (%)	Flow rate (mL/min)
0	65	35	0.30
4	40	60	0.30
12	15	85	0.30
21	0	100	0.30
24	0	100	0.30
28	65	35	0.30

[Experimental Example 12] Lipid metabolome analysis result of patient before antibiotic treatment (Tx0)

Comparison of lipid metabolite concentrations in serum samples extracted from serum samples of 145 patients infected with Mycobacterium avium complex (MAC) before antibiotic treatment (Tx0) and divided into 97 patients who will succeed and 48 patients who will fail after treatment To do this, we calculated lipid metabolites with high significance (p-value <0.05) between groups through Unpaired and Welch's T-test tests of Metaboanalyst (statistics site), Compound Discoverer of Thermofisher, and SPSS (statistics program) as a statistical test method. , The fold change value of the expression levels of patients who will succeed and patients who will fail before treatment and each p-value of lipid metabolites that can predict the treatment response of MAC patients before antibiotic treatment (Tx0) using the results Based on, a total of 8 species were selected, and the results are shown in Table 4 and FIG. 3 below. However, in FIG. 3, the expression level of each metabolite in the serum samples of 145 MAC-infected patients before treatment (Tx0_Success & Fail) is shown. In addition, significance unpaired, Welch's t-test *P<0.05; **P<0.01; ***P<0.001 means.

Lipid metabolites predicting treatment response in MAC patients before antibiotic treatment (Tx0)
Metabolite types (Compounds)	Significance (p-value)	Fold Change(F/S)
LPC 20:3	0.01	1.31
PC 28:0 (14:0/14:0)	0.026	1.32
PC 33:2 (18:2/15:0)	0.004	0.84
PC 34:3 (16:1/18:2)	0.005	0.82
PC 36:1 (18:0/18:1)	0.037	1.12
PC 36:3 (16:0/20:3)	0.043	1.11
SM d40:2 (d18:2/22:0)	0.029	0.90
SM d41:1 (d18:1/23:0)	0.032	0.87

[Experimental Example 13] Lipid metabolome analysis results according to lung disease type

Among 145 serum samples from patients with Mycobacterium avium complex (MAC) infection before antibiotic treatment (Tx0), 83 patients with Nodular bronchiectatic form (NB) and upper lobe cavitary form (UC) patients Metaboanalyst (statistics site), Compound Discoverer of Thermofisher, and SPSS (statistics program) Unpaired, Welch's T-test were used as statistical tests to compare lipid metabolite concentrations in serum samples from 31 patients and 31 patients who converted from NB to UC. Through the test, lipid metabolomes with high significance (p-value <0.05) between groups were calculated, and using the results, lipid metabolites that can predict the antibiotic treatment response by type of lung disease in MAC patients before antibiotic treatment (Tx0) Based on each p-value and fold change value, 1 type of nodular bronchiectatic form (NB), 2 types of upper lobe cavitary form (UC), and 1 type of conversion from NB to UC were selected. was selected, and the results are shown in Table 5 and Figures 4 to 6 below. However, in FIGS. 4 to 6, the expression level of each metabolite in the serum samples of 145 MAC-infected patients before treatment (Tx0_Success & Fail) is shown. In addition, significance unpaired, Welch's t-test *P<0.05; **P<0.01; ***P<0.001 means.

Lipid metabolome predicting treatment response in nodular bronchiectatic form (NB) patients (n=83)
Metabolite types (Compounds)	Significance (p-value)	Fold Change(F/S)
PC 28:0 (14:0/14:0)	0.038	1.46
Lipid metabolites predicting treatment response in upper lobe cavitary form (UC) patients (n=31)
LPE 22:6	0.043	1.38
PC 36:4 (20:4/16:0)	0.038	1.18
Lipid metabolome predictive treatment response in NB to UC form conversion (NB to UC) patients (n=31)
PC 33:2 (18:2/15:0)	0.008	0.75

[Experimental Example 14] Results of Lipid Metabolome Analysis According to Etiology of Infectious Bacteria

Before antibiotic treatment (Tx0), in order to compare lipid metabolite concentrations according to etiology ( M.avium , M.intracellulare ) among 145 serum samples from Mycobacterium avium complex (MAC) infected patients, Metaboanalyst was performed using the following statistical test method. (statistics site), Compound Discoverer of Thermofisher, SPSS (statistics program) Unpaired, Welch's T-test to calculate lipid metabolites with high significance (p-value <0.05) between groups, and antibiotics using the results. A total of 5 lipid metabolites, including 4 types of M.avium and 1 type of M.intracelluare , based on each p-value and fold change value, which can predict antibiotic treatment response according to the etiology of infectious bacteria in MAC patients before treatment (Tx0) Species were selected, and the results are shown in Table 6 and FIGS. 7 or 8 below. However, in FIG. 7 or 8, the expression level of each metabolite in the serum samples of 145 MAC-infected patients before treatment (Tx0_Success & Fail) is shown. In addition, significance unpaired, Welch's t-test *P<0.05;**P<0.01;***P<0.001 means.

M. avium Antibiotic Treatment Response Predictive Lipid Metabolites in MAC Patients with Fungal Infection
Metabolite types (Compounds)	Significance (p-value)	Fold Change(F/S)
PC 33:2 (18:2/15:0)	0.022	0.77
PC 34:3 (16:1/18:2)	0.03	0.77
SM d40:2 (d18:1/22:0)	0.016	0.85
SM d41:1 (d18:1/23:0)	0.024	0.79
M. intracellulare Lipid metabolome predicting response to antibiotic treatment in MAC patients with fungal infection
LPE 20:4	0.041	1.18

[Experimental Example 15] Results of Lipid Metabolome Analysis by Gender

Before antibiotic treatment (Tx0), Metaboanalyst (statistics site) was used to compare lipid metabolite concentrations according to sex (male, female) among 145 serum samples of patients infected with Mycobacterium avium complex (MAC) before antibiotic treatment (Tx0). Lipid metabolites with high significance (p-value <0.05) between groups were calculated through Unpaired, Welch's T-test of SPSS (statistics program) and Compound Discoverer of Thermofisher, and the results were used before antibiotic treatment (Tx0 ) Based on each p-value and fold change value, a total of 9 types, including 4 types for male patients and 5 types for female patients, were selected as lipid metabolites that can predict antibiotic treatment response according to the sex of MAC patients. And the results are shown in Table 7 and FIG. 9 or 10 below. However, in FIG. 9 or 10, the expression level of each metabolite in the serum samples of 145 MAC-infected patients before treatment (Tx0_Success & Fail) is shown. In addition, *P<0.05; **P<0.01; ***P<0.001 means.

Lipid metabolites that can predict antibiotic treatment response according to sex (male) of MAC patients
Metabolite types (Compounds)	Significance (p-value)	Fold Change(F/S)
LPC 20:3	0.008	1.58
PC 36:3 (16:0/20:3)	0.022	1.24
SM d34:1 (d18:1/16:0)	0.033	1.16
SM d36:1 (d18:1/18:0)	0.024	1.28
Lipid metabolites that can predict antibiotic treatment response according to sex (female) of MAC patients
PC 28:0 (14:0/14:0)	0.012	1.55
PC 30:0 (14:0/16:0)	0.022	1.32
PC 33:2 (18:2/15:0)	0.002	0.80
PC 36:1 (18:0/18:1)	0.018	1.20
SM d35:1 (d18:1/17:0)	0.029	0.86

[Experimental Example 16] Lipid metabolome analysis results according to body mass index (BMI)

Metaboanalyst (statistics site) using the following statistical test method to compare lipid metabolite concentrations according to BMI (Body Mass Index) among 145 serum samples from patients infected with Mycobacterium avium complex (MAC) before antibiotic treatment (Tx0) and Compound Discoverer of Thermofisher, SPSS (statistics program) Unpaired, Welch's T-test was used to calculate lipid metabolites with high significance (p-value <0.05) for each group (Low, Normal, Fat), and the results Lipid metabolites that can predict the antibiotic treatment response according to the BMI index of MAC patients before antibiotic treatment (Tx0) were classified into 5 types for BMI (Low) patients and BMI (Normal ) A total of 14 types were selected, including 6 types of patients and 3 types of BMI (Fat) patients, and the results are shown in Table 8 and FIGS. 11 to 13 below. However, in FIGS. 11 to 13, the expression level of each metabolite in the serum samples of 145 MAC-infected patients before treatment (Tx0_Success & Fail) is shown. In addition, *P<0.05; **P<0.01; ***P<0.001 means.

Antibiotic treatment response prediction according to BMI (Low) in MAC patients Lipid metabolites
Metabolite types (Compounds)	Significance (p-value)	Fold Change(F/S)
SM d35:1 (d18:1/17:0)	0.001	0.72
TAG 55:7 (21:5/18:2/16:0)	0.049	0.46
TAG 58:11(22:6/20:5/16:0)	0.022	0.38
TAG 60:11 (22:6/20:4/18:1)	0.042	0.51
TAG 60:12(22:6/22:6/16:0)	0.009	0.34
Prediction of antibiotic treatment response according to BMI (Normal) in MAC patients Lipid metabolites
PC 33:2 (18:2/15:0)	0.003	0.80
PC 34:2 (18:2/16:0)	0.015	0.90
PC 34:3 (16:1/18:2)	0.036	0.83
PC 36:1 (18:0/18:1)	0.015	1.21
PC 36:2 (18:0/18:2)	0.024	0.91
PE-NME 34:1 (18:1/16:0)	0.040	1.11
Prediction of antibiotic treatment response according to BMI (Fat) of MAC patients Lipid metabolites
LPC 14:0	0.003	1.71
LPC 15:0	0.005	1.55
PC 36:6 (14:0/22:6)	0.002	1.76

Since the specific parts of the present invention have been described in detail above, it is clear that these specific techniques are only preferred embodiments for those skilled in the art, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

The present invention is an infectious disease caused by Nontuberculous mycobacteria (NTM), in particular, Mycobacterium avium complex (MAC), which causes lung diseases very commonly in humans, for which it is difficult to develop objective and reliable diagnostic markers. For the development of markers for predicting the responsiveness of antibiotic treatment in patients of Recently, reports of lung infections caused by non-tuberculous mycobacteria are increasing worldwide, but the lack of research on antibiotic treatment responsiveness in infected patients has been reported as a problem, and the need for their development is required. The present invention provides 10 types of lipid metabolites capable of predicting the antibiotic treatment responsiveness and treatment success probability of patients infected with non-tuberculous mycobacteria with high reproducibility, and the possibility of antibiotic treatment response success of infected patients according to patient characteristics such as gender and body mass index. Accordingly, 40 lipid metabolites that can be predicted with high reproducibility were discovered as markers. As a result, it is expected to be usefully used to significantly improve the survival rate of patients by determining the treatment responsiveness of patients infected with non-tuberculous mycobacteria and establishing a patient-specific treatment strategy at an early stage.

Claims (43)

1. An agent for measuring one or more metabolites selected from the group consisting of Lysophosphatidylethanolamine (LPE), Phosphatidylcholine (PC), Sphingomyeline (SM) and Triacylglycerol (TAG) A composition for predicting treatment responsiveness to antibiotics in patients infected with non-tuberculosis mycobacteria, comprising as an active ingredient.
2. According to claim 1,

   The composition, characterized in that the lysophosphatidylethanolamine is LPE (18: 2).
3. According to claim 1,

   The phosphatidylcholine is PC 34:3 (16:1/18:2), PC 36:1 (18:0/18:1), PC 36:2 (18:0/18:2), PC 28:0 ( 14:0/14:0) and at least one phosphatidylcholine selected from the group consisting of PC 30:0 (14:0/16:0).
4. According to claim 1,

   The composition, characterized in that the sphingomyelin is SM d36:2 (d18:1/18:1).
5. According to claim 1,

   The triacylglycerol is TAG 55:7 (21:5/18:2/16:0), TAG 58:11 (22:6/20:5/16:0) and TAG 60:11 (22:6/ 20:4/18:1), characterized in that at least one triacylglycerol selected from the group consisting of.
6. According to claim 1,

   When the concentration of the sphingomyelin before administration of the antibiotic is lower than the concentration measured after administration of the antibiotic, the patient infected with the non-tuberculous mycobacteria is determined to have a therapeutic response to the antibiotic.
7. According to claim 1,

   When the concentration of the triacylglycerol before administration of the antibiotic is higher than the concentration measured after administration of the antibiotic, the patient infected with the non-tuberculous mycobacteria is determined to have a therapeutic response to the antibiotic.
8. According to claim 3,

   If the concentration of the phosphatidylcholine (PC 36:1 (18:0/18:0)) or PC 36:2 (18:0/18:2) before antibiotic administration is lower than the concentration measured after antibiotic administration, the non-tuberculosis A composition characterized in that a patient infected with acid-fast bacteria is determined to have a therapeutic response to an antibiotic.
9. According to claim 3,

   If the concentration of the phosphatidylcholine (PC 34:3 (16:1/18:2)) before administration of antibiotics is higher than the concentration measured after administration of antibiotics, the patient infected with the non-tuberculosis mycobacterium has a therapeutic response to antibiotics. A composition characterized in that it is determined to be.
10. According to claim 3,

    The concentration of the lysophosphatidylethanolamine (LPE (18:2)), phosphatidylcholine (PC 28:0 (14:0/14:0)) or PC 30:0 (14:0/16:0) before antibiotic administration If the concentration is higher than the concentration measured after administration of the antibiotic, it is characterized in that the patient infected with the non-tuberculous mycobacteria is determined to have a therapeutic response to the antibiotic.
11. According to any one of claims 7 to 10,

    Composition characterized in that the measurement after administration of the antibiotic is performed after 2 to 4 months after administration of the antibiotic.
12. According to claim 1,

    The metabolites are whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears ( tears, mucus, nasal washes, nasal aspirates, breath, urine, semen, saliva, peritoneal washings, Ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple Nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cells, cell extract and cerebrospinal fluid ( A composition characterized by being present in cerebrospinal fluid).
13. According to claim 1,

    The non-tuberculous acidophilus is Mycobacterium avium ( M. avium ), Mycobacterium absesus ( M. abscessus ), Mycobacterium flavescence ( M. flavescence ), Mycobacterium africanum ( M. africanum ), Mycobacterium bovis ( M. bovis ), Mycobacterium chelone ( M. chelonae ), Mycobacterium cellatum ( M. celatum ), Mycobacterium fortuitum ( M. fortuitum ), Mycobacterium gordonae ( M. gordonae ), Mycobacterium gastri ( M. gastri ), Mycobacterium hemophilum ( M. haemophilum ), Mycobacterium intracellurare ( M. intracellulare ), Mycobacterium Kansasii ( M. kansasii ), Mycobacterium malmoenseu ( M. malmoense ), Mycobacterium marinum ( M. marinum ), Mycobacterium suzulgai ( M. szulgai ) , Mycobacterium terae ( M. terrae ), Mycobacterium scrofulaceum ( M. scrofulaceum ), Mycobacterium Ulceranseu ( M. ulcerans ), Mycobacterium simiae ( M. simiae ) and A composition characterized in that it is selected from the group consisting of Mycobacterium xenopi ( M. xenopi ).
14. Lysophosphatidylethanolamine, phosphatidylcholine, sphingomyeline, and triacylglycerol in non-tuberculous mycobacteria, including the step of measuring one or more metabolites selected from the group consisting of A method for providing information to predict treatment responsiveness to antibiotics in patients infected with
15. According to claim 14,

    Wherein the step of measuring the concentration of the metabolite is performed using a quantitative device such as chromatography or mass spectrometry.
16. Use of lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), sphingomyelin (SM) and triacylglycerol (TAG) to predict treatment responsiveness to antibiotics in patients infected with nontuberculous mycobacteria.
17. Lysophosphatidylcholine (LPC), Lysophosphatidylethanolamine (LPE), Phosphatidylcholine (PC), Phosphatidylethanolamine (PE), Sphingomyeline (SM) and triacylglycerol; A composition for predicting treatment responsiveness to antibiotics in patients infected with non-tuberculosis mycobacteria, comprising as an active ingredient an agent for measuring one or more metabolites selected from the group consisting of (TAG).
18. According to claim 17,

    The composition, characterized in that the lysophosphatidylcholine is at least one lysophosphatidylcholine selected from the group consisting of LPC (20:3), LPC (14:0) and LPC (15:0).
19. According to claim 17,

    The composition, characterized in that the lysophosphatidylethanolamine is at least one lysophosphatidylethanolamine selected from the group consisting of LPE (22:6) and LPE (20:4).
20. According to claim 17,

    The phosphatidylcholine is PC 28:0 (14:0/14:0), PC 33:2 (18:2/15:0)), PC 34:3 (16:1/18:2), PC 36:1 (18:0/18:1), PC 36:3 (16:0/20:3), PC 36:4 (20:4/16:0), PC 28:0 (14:0/14:0 ), PC 30:0 (14:0/16:0), PC 34:2 (18:2/16:0), PC 36:2 (18:0/18:2) and PC 36:6 (14 :0/22:6), characterized in that at least one phosphatidylcholine selected from the group consisting of.
21. According to claim 17,

    The composition, characterized in that the phosphatidylethanolamine is PE--NME 34: 1 (18: 1 / 16: 0).
22. According to claim 17,

    The sphingomyelin is SM d40:2 (d18:2/22:0), SM d41:1 (d18:1/23:0), SM d34:1 (d18:1/16:0), SM d36 :1 (d18:1/18:0) and at least one sphingomyelin selected from the group consisting of SM d35:1 (d18:1/17:0).
23. According to claim 17,

    The triacylglycerol is TAG 55:7 (21:5/18:2/16:0), TAG 58:11 (22:6/20:5/16:0), TAG 60:11 (22:6/ 20:4/18:1) and at least one triacylglycerol selected from the group consisting of TAG 60:12 (22:6/22:6/16:0).
24. According to claim 17,

    The lysophosphatidylcholine (LPC 18:0), phosphatidylcholine (PC 28:0 (14:0/14:0)), PC 36:1 (18:0) in patients infected with the non-tuberculous mycobacteria measured before antibiotic administration /18:1) or PC 36:3 (16:0/20:3), if the concentration is lower than the concentration measured in patients who do not respond to antibiotics, patients infected with the non-tuberculous mycobacteria are treated with antibiotics. A composition characterized in that it is determined that there is a therapeutic response to.
25. According to claim 17,

    The phosphatidylcholine (PC 33:2 (18:2/15:0)), PC 34:3 (16:1/18:2), sphingomycin in patients infected with the non-tuberculous mycobacteria measured before antibiotic administration If the concentration of elin (SM d40:2 (d18:2/22:0)) or SM d41:1 (d18:1/23:0) is higher than the concentration measured in patients not responding to antibiotics, A composition characterized in that a patient infected with non-tuberculous mycobacteria is determined to have a therapeutic response to antibiotics.
26. According to claim 17,

    The concentration of the phosphatidylcholine (PC 28:0 (14:0/14:0)) in patients infected with the non-tuberculous mycobacterium measured before antibiotic administration in patients with nodular bronchiectatic form was treated with antibiotics. When the concentration is lower than the concentration measured in the non-responsive patient, the composition characterized in that the patient infected by the non-tuberculosis mycobacteria is determined to have a therapeutic response to the antibiotic.
27. According to claim 17,

    The lysophosphatidylethanolamine (LPE (22:6)) or phosphatidylcholine (PC 36:4 (20:4 / 16: 0)) is lower than the concentration measured in patients without treatment responsiveness to antibiotics, the patient infected with the non-tuberculosis mycobacterium is a composition characterized in that it is determined that there is treatment responsiveness to antibiotics .
28. According to claim 17,

    The concentration of the phosphatidylcholine (PC 33:2 (18:2/15:0)) in the patient infected with the non-tuberculous mycobacterium measured before antibiotic administration in a patient who converted from nodular bronchiectasis type to upper lobe cavity type was compared to antibiotics. When the concentration is higher than the concentration measured in patients without treatment responsiveness to the composition, it is characterized in that the patient infected by the non-tuberculosis mycobacteria is determined to have treatment responsiveness to antibiotics.
29. According to claim 17,

    Mycobacterium avium ( Mycobacterium avium ) The phosphatidylcholine (PC 33:2 (18:2/15:0)) in patients infected with the non-tuberculous mycobacteria measured before antibiotic administration in patients infected by bacteria, PC Concentrations of 34:3 (16:1/18:2), sphingomyelin (SM d40:2 (d18:2/22:0)) or SM d41:1 (d18:1/23:0) were antibiotics If the concentration is higher than the concentration measured in patients without treatment responsiveness to, the composition characterized in that the patient infected by the non-tuberculous mycobacteria is determined to have treatment responsiveness to antibiotics.
30. According to claim 17,

    The concentration of the lysophosphatidylethanolamine (LPE (20:4)) in the patient infected with the non-tuberculosis mycobacteria measured before administration of antibiotics in patients infected with Mycobacterium intracellulare bacteria was found in antibiotics. When the concentration is lower than the concentration measured in patients without treatment responsiveness to the composition, characterized in that the patient infected by the non-tuberculosis mycobacteria is determined to have treatment responsiveness to antibiotics.
31. According to claim 17,

    The lysophosphatidylcholine (LPC 20:3), phosphatidylcholine (PC 36:3 (16:0/20:3)), sphingomyelin ( If the concentration of SM d34:1 (d18:1/16:0)) or SM d36:1 (d18:1/18:0) is lower than the concentration measured in patients unresponsive to antibiotics, the non-tuberculous A composition characterized in that a patient infected with acid-fast bacteria is determined to have a therapeutic response to an antibiotic.
32. According to claim 17,

    The phosphatidylcholine (PC 28:0 (14:0/14:0)), PC 30:0 (14:0/16:0), or If the concentration of PC 36:1 (18:0/18:1) is lower than the concentration measured in patients with no treatment response to antibiotics, the patient infected with the non-tuberculosis mycobacteria is considered to have treatment response to antibiotics. Composition characterized in that the determination.
33. According to claim 17,

    The phosphatidylcholine (PC 33:2 (18:2/15:0)) or sphingomyelin (SM d35:1 (d18:1/ 17:0)) is higher than the concentration measured in patients who do not have treatment responsiveness to antibiotics, the patient infected with the non-tuberculous mycobacteria is determined to have treatment responsiveness to antibiotics.
34. According to claim 17,

    The sphingomyelin (SM d35:1 (d18:1/17:0)) in a patient infected with the non-tuberculous mycobacterium measured before antibiotic administration in a patient with a low body mass index, Triacylglycerol (TAG 55:7 (21:5/18:2/16:0)), TAG 58:11 (22:6/20:5/16:0), TAG 60:11 (22:6/ 20:4/18:1) or TAG 60:12 (22:6/22:6/16:0) when the concentration is higher than the concentration measured in patients who are not responsive to antibiotics, the non-tuberculous mycobacteria A composition characterized in that the patient infected by is determined to have a therapeutic response to antibiotics.
35. According to claim 17,

    The phosphatidylcholine (PC 33:2 (18:2/15:0)), PC 34 in a patient infected with the non-tuberculous mycobacterium measured before antibiotic administration in a patient with a normal body mass index :2 (18:2/16:0), PC 34:3 (16:1/18:2), or PC 36:2 (18:0/18:2) concentration in patients with no treatment response to antibiotics When higher than the concentration measured in, the patient infected with the non-tuberculous mycobacterium is a composition characterized in that it is determined that there is a therapeutic response to the antibiotic.
36. According to claim 17,

    The phosphatidylcholine (PC 36:1 (18:0/18:1)) or phosphatidylethanolamine (PE- -If the concentration of NME 34:1 (18:1/16:0)) is lower than the concentration measured in patients with no treatment response to antibiotics, patients infected with the non-tuberculosis mycobacterium have a treatment response to antibiotics A composition characterized in that it is determined that there is.
37. According to claim 17,

    The lysophosphatidylcholine (LPC 14:0), LPC (15:0) or phosphatidylcholine (PC 36 If the concentration of :6 (14:0/22:6)) is lower than the concentration measured in patients with no treatment response to antibiotics, the patient infected with the non-tuberculous mycobacteria is judged to have treatment response to antibiotics. Composition characterized in that to.
38. 38. The method of any one of claims 35 to 37,

    The body mass index is low for patients with a body mass index of less than 18.5, normal for patients with a body mass index of 18.5 or more and less than 23, and high for patients with a body mass index of 23 or more.
39. According to claim 17,

    The metabolites are whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears ( tears, mucus, nasal washes, nasal aspirates, breath, urine, semen, saliva, peritoneal washings, Ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple Nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cells, cell extract and cerebrospinal fluid ( A composition characterized by being present in cerebrospinal fluid).
40. According to claim 17,

    The non-tuberculous acidophilus is Mycobacterium avium ( M. avium ), Mycobacterium absesus ( M. abscessus ), Mycobacterium flavescence ( M. flavescence ), Mycobacterium africanum ( M. africanum ), Mycobacterium bovis ( M. bovis ), Mycobacterium chelone ( M. chelonae ), Mycobacterium cellatum ( M. celatum ), Mycobacterium fortuitum ( M. fortuitum ), Mycobacterium gordonae ( M. gordonae ), Mycobacterium gastri ( M. gastri ), Mycobacterium hemophilum ( M. haemophilum ), Mycobacterium intracellurare ( M. intracellulare ), Mycobacterium Kansasii ( M. kansasii ), Mycobacterium malmoenseu ( M. malmoense ), Mycobacterium marinum ( M. marinum ), Mycobacterium suzulgai ( M. szulgai ) , Mycobacterium terae ( M. terrae ), Mycobacterium scrofulaceum ( M. scrofulaceum ), Mycobacterium Ulceranseu ( M. ulcerans ), Mycobacterium simiae ( M. simiae ) and A composition characterized in that it is selected from the group consisting of Mycobacterium xenopi ( M. xenopi ).
41. At least one metabolite selected from the group consisting of Lysophosphatidylcholine, Lysophosphatidylethanolamine, Phosphatidylcholine, Phosphatidylethanolamine, Sphingomyeline and Triacylglycerol Information providing method for predicting the treatment responsiveness of patients infected with non-tuberculous mycobacteria, comprising the step of measuring.
42. 42. The method of claim 41,

    Wherein the step of measuring the concentration of the metabolite is performed using a quantitative device such as chromatography or mass spectrometry.
43. Lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM) and triglycerides for predicting treatment responsiveness of patients infected with non-tuberculous mycobacteria Uses of Acylglycerols (TAGs).

Images